This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Nolden, S Articles by Petereit, H F Search for Related Content PubMed PubMed Citation Articles by Nolden, S Articles by Petereit, H F Social Bookmarking                         What's this?

Jessner-Kanof lymphocytic infiltration of the skin associated with glatiramer acetate

Department of Neurology, University of Cologne, 50924 Cologne, Germany, silkenolden{at}gmx.de

C Casper

Dermatohistologisches Gemeinschaftsabor, 50997 Cologne, Germany

A Kuhn

Dermatohistologisches Gemeinschaftsabor, 50997 Cologne, Germany

H F Petereit

Department of Neurology, University of Cologne, 50924 Cologne, Germany

Glatiramer acetate (GLAT) is a well tolerated and safe immunomodulatory drug for the treatment of relapsing=remitting multiple sclerosis. The most commonly recognized side effects are localized injection site reactions consisting of pain, pruritus, mild erythema and induration, which sometimes persist for several days. We describe the first case of a biopsy-proven lymphocytic infiltration (T-cell pseudolymphoma) with the clinical appearance of a figured erythema on the ventrolateral thighs in the first four weeks under GLAT treatment, resolving without any evidence of recurrence despite ongoing therapy. A T-cell pseudolymphoma is a very rare side effect of GLAT treatment. For clinical purposes it is important to state that re-exposition after GLAT-induced pseudolymphoma is possible without permanent sequelae.

Key Words: glatiramer acetate • infiltration • Jessner-Kanof • lymphocytic infiltration • multiple sclerosis • pseudolymphoma • side effect

Multiple Sclerosis, Vol. 11, No. 2, 245-248 (2005)
DOI: 10.1191/1352458505ms1130cr


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. M. Madray, J. F. Greene Jr, and D. F. Butler Glatiramer Acetate-Associated, CD30+, Primary, Cutaneous, Anaplastic Large-Cell Lymphoma Arch Neurol, October 1, 2008; 65(10): 1378 - 1379. [Abstract] [Full Text] [PDF]

				A. Ardavanis, G. Orphanos, S. Skafida, S. Basioukas, and G. Rigatos Coincidential successful treatment of Jessner-Kanof disease with chemotherapy Ann. Onc., July 1, 2008; 19(7): 1360 - 1361. [Full Text] [PDF]

				E. Thouvenot, D. Hillaire-Buys, M.A. Bos-Thompson, V. Rigau, L. Durand, B. Guillot, and W. Camu Erythema nodosum and glatiramer acetate treatment in relapsing-remitting multiple sclerosis Multiple Sclerosis, August 1, 2007; 13(7): 941 - 944. [Abstract] [PDF]

				T. E. Witzig, D. J. Inwards, T. M. Habermann, A. Dogan, P. J. Kurtin, J. B. Gross Jr, A. Ananthamurthy, K. M. Ristow, and J. A. Garrity Treatment of Benign Orbital Pseudolymphomas With the Monoclonal Anti-CD20 Antibody Rituximab Mayo Clin. Proc., June 1, 2007; 82(6): 692 - 699. [Abstract] [Full Text] [PDF]